In and Out: Traffic and Dynamics of Thrombopoietin Receptor

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2021 Aug 27

PMID 34448528

Citations 5

Authors

Anita Roy

Saurabh Shrivastva

Saadia Naseer

Affiliations

Soon will be listed here.

Abstract

Thrombopoiesis had long been a challenging area of study due to the rarity of megakaryocyte precursors in the bone marrow and the incomplete understanding of its regulatory cytokines. A breakthrough was achieved in the early 1990s with the discovery of the thrombopoietin receptor (TpoR) and its ligand thrombopoietin (TPO). This accelerated research in thrombopoiesis, including the uncovering of the molecular basis of myeloproliferative neoplasms (MPN) and the advent of drugs to treat thrombocytopenic purpura. TpoR mutations affecting its membrane dynamics or transport were increasingly associated with pathologies such as MPN and thrombocytosis. It also became apparent that TpoR affected hematopoietic stem cell (HSC) quiescence while priming hematopoietic stem cells (HSCs) towards the megakaryocyte lineage. Thorough knowledge of TpoR surface localization, dimerization, dynamics and stability is therefore crucial to understanding thrombopoiesis and related pathologies. In this review, we will discuss the mechanisms of TpoR traffic. We will focus on the recent progress in TpoR membrane dynamics and highlight the areas that remain unexplored.

Citing Articles

A review on the functional characteristics of the c-Myeloproliferative Leukaemia (c-MPL) gene and its isoforms.

Hussain M, Das S, Kulkarni M, Laha S Cell Oncol (Dordr). 2024; 47(5):1607-1626.

PMID: 39283476 DOI: 10.1007/s13402-024-00988-w.

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers.

Moufarrij S, OCearbhaill R, Zhou Q, Iasonos A, Mantha S, Zwicker J Gynecol Oncol Rep. 2024; 53:101399.

PMID: 38757118 PMC: 11096926. DOI: 10.1016/j.gore.2024.101399.

Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease.

Behrens K, Kauppi M, Viney E, Kueh A, Hyland C, Willson T Leukemia. 2024; 38(6):1342-1352.

PMID: 38491305 PMC: 11147766. DOI: 10.1038/s41375-024-02219-5.

Effects of calreticulin mutations on cell transformation and immunity.

Desikan H, Kaur A, Pogozheva I, Raghavan M J Cell Mol Med. 2023; 27(8):1032-1044.

PMID: 36916035 PMC: 10098294. DOI: 10.1111/jcmm.17713.

In and out: Traffic and dynamics of thrombopoietin receptor.

Roy A, Shrivastva S, Naseer S J Cell Mol Med. 2021; 25(19):9073-9083.

PMID: 34448528 PMC: 8500957. DOI: 10.1111/jcmm.16878.

References

Ng A, Kauppi M, Metcalf D, Hyland C, Josefsson E, Lebois M . Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci U S A. 2014; 111(16):5884-9. PMC: 4000844. DOI: 10.1073/pnas.1404354111. View

Dagil R, Knudsen M, Olsen J, OShea C, Franzmann M, Goffin V . The WSXWS motif in cytokine receptors is a molecular switch involved in receptor activation: insight from structures of the prolactin receptor. Structure. 2012; 20(2):270-82. DOI: 10.1016/j.str.2011.12.010. View

Varghese L, Zhang J, Young S, Willson T, Alexander W, Nicola N . Functional characterization of c-Mpl ectodomain mutations that underlie congenital amegakaryocytic thrombocytopenia. Growth Factors. 2014; 32(1):18-26. DOI: 10.3109/08977194.2013.874347. View

Gurney A, Wong S, Henzel W, de Sauvage F . Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci U S A. 1995; 92(12):5292-6. PMC: 41680. DOI: 10.1073/pnas.92.12.5292. View

Lannutti B, Drachman J . Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors. Blood. 2004; 103(10):3736-43. DOI: 10.1182/blood-2003-10-3566. View

Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A . c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97(1):139-46. DOI: 10.1182/blood.v97.1.139. View

Martinez-Fabregas J, Wilmes S, Wang L, Hafer M, Pohler E, Lokau J . Kinetics of cytokine receptor trafficking determine signaling and functional selectivity. Elife. 2019; 8. PMC: 6914340. DOI: 10.7554/eLife.49314. View

Banerjee M, Joshi S, Zhang J, Moncman C, Yadav S, Bouchard B . Cellubrevin/vesicle-associated membrane protein-3-mediated endocytosis and trafficking regulate platelet functions. Blood. 2017; 130(26):2872-2883. PMC: 5746669. DOI: 10.1182/blood-2017-02-768176. View

Defour J, Levy G, Leroy E, Smith S, Constantinescu S . The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters. Leukemia. 2019; 33(2):563-564. DOI: 10.1038/s41375-018-0356-x. View

10.

Matthews E, Thevenin D, Rogers J, Gotow L, Lira P, Reiter L . Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 2011; 25(7):2234-44. PMC: 3114528. DOI: 10.1096/fj.10-178673. View

11.

Gandhi H, Worch R, Kurgonaite K, Hintersteiner M, Schwille P, Bokel C . Dynamics and interaction of interleukin-4 receptor subunits in living cells. Biophys J. 2014; 107(11):2515-27. PMC: 4255262. DOI: 10.1016/j.bpj.2014.07.077. View

12.

Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y . Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia. 2018; 33(1):122-131. DOI: 10.1038/s41375-018-0181-2. View

13.

Foster D, Sprecher C, Grant F, Kramer J, Kuijper J, Holly R . Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1994; 91(26):13023-7. PMC: 45573. DOI: 10.1073/pnas.91.26.13023. View

14.

Deane C, Kroemer R, Richards W . A structural model of the human thrombopoietin receptor complex. J Mol Graph Model. 1997; 15(3):170-8, 185-8. DOI: 10.1016/s1093-3263(97)00102-2. View

15.

Gurney A, de Sauvage F, Moore M . Thrombocytopenia in c-mpl-deficient mice. Science. 1994; 265(5177):1445-7. DOI: 10.1126/science.8073287. View

16.

Royer Y, Staerk J, Costuleanu M, Courtoy P, Constantinescu S . Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005; 280(29):27251-61. DOI: 10.1074/jbc.M501376200. View

17.

Basso-Valentina F, Levy G, Varghese L, Oufadem M, Neven B, Boussard C . CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. Blood. 2021; 138(6):480-485. DOI: 10.1182/blood.2020010567. View

18.

Lok S, Kaushansky K, Holly R, Kuijper J, Oort P, Grant F . Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994; 369(6481):565-8. DOI: 10.1038/369565a0. View

19.

Kimura S, Roberts A, Metcalf D, Alexander W . Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998; 95(3):1195-200. PMC: 18717. DOI: 10.1073/pnas.95.3.1195. View

20.

Vigon I, Mornon J, Cocault L, Mitjavila M, Tambourin P, Gisselbrecht S . Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992; 89(12):5640-4. PMC: 49348. DOI: 10.1073/pnas.89.12.5640. View